Potential role of poly (ADP‑ribose) polymerase in delayed cerebral vasospasm following subarachnoid hemorrhage in rats

Fan,Yameng; Yan,Ge; Liu,Furong; Rong,Jie; Ma,Wenxia; Yang,Danrong; Yu,Yan

doi:10.3892/etm.2018.7073

Potential role of poly (ADP‑ribose) polymerase in delayed cerebral vasospasm following subarachnoid hemorrhage in rats

Authors:
- Yameng Fan
- Ge Yan
- Furong Liu
- Jie Rong
- Wenxia Ma
- Danrong Yang
- Yan Yu
View Affiliations

Affiliations: Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Medical Image, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: December 7, 2018 https://doi.org/10.3892/etm.2018.7073
Pages: 1290-1299
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Poly (ADP‑ribose) polymerase (PARP) serves a key role in several neurological disorders, however, the specific role of PARP in delayed cerebral vasospasm (DCVS) following subarachnoid hemorrhage (SAH) remains unclear. The present study was conducted to clarify the possible mechanism of PARP in DCVS with the treatment of 3‑aminobenzamide (3‑AB), a PARP inhibitor. In the preliminary experiment, an internal carotid artery puncture SAH model, a cisterna magna double injection SAH model and prechiasmatic cistern single injection SAH model were compared with respect to mortality and neurobehavioral test results. The prechiasmatic cistern single injection SAH model was chosen to induce DCVS in the formal experiment. In the formal experiment, a total of 96 Sprague Dawley rats were randomly allocated into the sham group, the SAH group and the SAH+3‑AB group and then each group was further subdivided into days 3, 5, 7 and 14 post‑SAH subgroups (n=8 for each subgroup). The prechiasmatic cistern single injection SAH model was established to induce DCVS. Neurobehavioral testing and HE staining were conducted to evaluate the degree of cerebral vasospasm. PARP activity was assessed by ELISA and immunohistochemistry. An electrophoretic mobility shift assay was used to detect nuclear factor (NF)‑κB DNA‑binding activity. The expression of monocyte chemotactic protein 1 (MCP‑1) and C‑reactive protein (CRP) were measured by western blotting. Cerebral vasospasm occurred following SAH and became most severe on around day 7 post‑SAH. NF‑κB activity, PARP activity, the expression of MCP‑1 and CRP exhibited a similar time course to cerebral vasospasm. Treatment with 3‑AB alleviated the degree of cerebral vasospasm. NF‑κB activity, PARP activity and the expression of MCP‑1 and CRP were also suppressed by 3‑AB treatment. In conclusion, PARP may serve an important role in regulating the inflammatory response and ultimately contribute to DCVS. Therefore 3‑AB may be a potential therapeutic agent for DCVS.

View Figures

View References

1	Treggiarivenzi MM, Suter PM and Romand JA: Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: A problem of neurointensive care. Neurosurgery. 48:249–262. 2001. View Article : Google Scholar : PubMed/NCBI
2	Woo D and Broderick JP: Spontaneous intracerebral hemorrhage: Epidemiology and clinical presentation. Neurosurg Clin N Am. 13:265–279.v. 2002. View Article : Google Scholar : PubMed/NCBI
3	Gules I, Satoh M, Clower BR, Nanda A and Zhang JH: Comparison of three rat models of cerebral vasospasm. Am J Physiol Heart Circ Physiol. 283:H2551–H2559. 2002. View Article : Google Scholar : PubMed/NCBI
4	Cecon AD, Figueiredo EG, Bor-seng-shu E, Scaff M and Teixeira MJ: Extremely delayed cerebral vasospasm after subarachnoid hemorrhage. Arq Neuropsiquiatr. 66:554–556. 2008. View Article : Google Scholar : PubMed/NCBI
5	Wu Q, Zheng R, Wang J, Wang J and Li S: CT perfusion imaging of cerebral microcirculatory changes following subarachnoid hemorrhage in rabbits: Specific role of endothelin-1 receptor antagonist. Brain Res. Sep 20–2018.(Epub ahead of print). View Article : Google Scholar
6	Yatsushige H, Yamaguchi M, Zhou C, Calvert JW and Zhang JH: Role of c-Jun N-terminal kinase in cerebral vasospasm after experimental subarachnoid hemorrhage. Stroke. 36:1538–1543. 2005. View Article : Google Scholar : PubMed/NCBI
7	Handa Y and Kubota T, Kaneko M, Tsuchida A, Kobayashi H, Kawano H and Kubota T: Expression of intercellular adhesion molecule 1 (ICAM-1) on the cerebral artery following subarachnoid haemorrhage in rats. Acta Neurochir (Wien). 132:92–97. 1995. View Article : Google Scholar : PubMed/NCBI
8	Zhang J, Xu X, Zhou D, Li H, You W, Wang Z and Chen G: Possible role of Raf-1 kinase in the development of cerebral vasospasm and early brain injury after experimental subarachnoid hemorrhage in rats. Mol Neurobiol. 52:1527–1539. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zhou ML, Shi JX, Hang CH, Cheng HL, Qi XP, Mao L, Chen KF and Yin HX: Potential contribution of nuclear factor-kappaB to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. J Cereb Blood Flow Metab. 27:1583–1592. 2007. View Article : Google Scholar : PubMed/NCBI
10	Pacher L and Szabó C: Role of Poly(ADP-Ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal. 7:1568–1580. 2005. View Article : Google Scholar : PubMed/NCBI
11	Pacher P, Mabley JG, Soriano FG, Liaudet L and Szabó C: Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int J Mol Med. 9:659–664. 2002.PubMed/NCBI
12	Hassa PO, Buerki C, Lombardi C, Imhof R and Hottiger MO: Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by Poly(ADP)-ribose polymerase-1. J Biol Chem. 278:45145–45153. 2003. View Article : Google Scholar : PubMed/NCBI
13	Saravanan S, Islam VI, Babu NP, Pandikumar P, Thirugnanasambantham K, Chellappandian M, Raj CS, Paulraj MG and Ignacimuthu S: Swertiamarin attenuates inflammation mediators via modulating NF-κB/I κB and JAK2/STAT3 transcription factors in adjuvant induced arthritis. Eur J Pharm Sci. 56:70–86. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kaoutzanis M, Yokota M, Sibilia R and Peterson JW: Neurologic evaluation in a canine model of single and double subarachnoid hemorrhage. J Neurosci Methods. 50:301–307. 1993. View Article : Google Scholar : PubMed/NCBI
15	Xiong Y, Wang XM, Zhong M, Li ZQ, Wang Z, Tian ZF, Zheng K and Tan XX: Alterations of caveolin-1 expression in a mouse model of delayed cerebral vasospasm following subarachnoid hemorrhage. Exp Ther Med. 12:1993–2002. 2016. View Article : Google Scholar : PubMed/NCBI
16	Shao A, Guo S, Tu S, Ammar AB, Tang J, Hong Y, Wu H and Zhang J: Astragaloside IV alleviates early brain injury following experimental subarachnoid hemorrhage in rats. Int J Med Sci. 11:1073–1081. 2014. View Article : Google Scholar : PubMed/NCBI
17	Grasso G: An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage. Brain Res Brain Res Rev. 44:49–63. 2004. View Article : Google Scholar : PubMed/NCBI
18	Specogna AV: Subarachnoid hemorrhage diagnosis. JAMA. 311:2012014. View Article : Google Scholar : PubMed/NCBI
19	Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JA, Larsen AK and Saffi J: PARPs and the DNA damage response. Carcinogenesis. 33:1433–1440. 2012. View Article : Google Scholar : PubMed/NCBI
20	Chai WN, Sun XC, Lv FJ, Wan B and Jiang L: Clinical study of changes of cerebral microcirculation in cerebral vasospasm after SAH. Acta Neurochir Suppl. 110:225–228. 2011.PubMed/NCBI
21	Mutch WA: New concepts regarding cerebral vasospasm: Glial-centric mechanisms. Can J Anaesth. 57:479–489. 2010. View Article : Google Scholar : PubMed/NCBI
22	Yan JH, Yang XM, Chen CH, Hu Q, Zhao J, Shi XZ, Luan LJ, Yang L, Qin LH and Zhou CM: Pifithrin-alpha reduces cerebral vasospasm by attenuating apoptosis of endothelial cells in a subarachnoid haemorrhage model of rat. Chin Med J (Engl). 121:414–419. 2008.PubMed/NCBI
23	Pluta RM: Introduction to problems of postsubarachnoid hemorrhage delayed cerebral vasospasm. Animal Models of Acute Neurological Injuries II. 459–464. 2012. View Article : Google Scholar
24	Lin C, Zhao Y, Wan G, Zhu A and Wang H: Effects of simvastatin and taurine on delayed cerebral vasospasm following subarachnoid hemorrhage in rabbits. Exp Ther Med. 11:1355–1360. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zaheer A, Sahu SK, Wu Y, Zaheer A, Haas J, Lee K and Yang B: Diminished cytokine and chemokine expression in the central nervous system of GMF-deficient mice with experimental autoimmune encephalomyelitis. Brain Res. 1144:239–247. 2007. View Article : Google Scholar : PubMed/NCBI
26	Thompson WL, Karpus WJ and Van Eldik LJ: MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation. 5:352008. View Article : Google Scholar : PubMed/NCBI
27	Lu H, Shi JX, Chen HL, Hang CH, Wang HD and Yin HX: Expression of monocyte chemoattractant protein-1 in the cerebral artery after experimental subarachnoid hemorrhage. Brain Res. 1262:73–80. 2009. View Article : Google Scholar : PubMed/NCBI
28	Buckley DI, Fu R, Freeman M, Rogers K and Helfand M: C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med. 151:483–495. 2009. View Article : Google Scholar : PubMed/NCBI
29	Elkind MS, Luna JM, Moon YP, Liu KM, Spitalnik SL, Paik MC and Sacco RL: High-sensitivity C-reactive protein predicts mortality but not stroke the northern manhattan study. Neurology. 73:1300–1307. 2009. View Article : Google Scholar : PubMed/NCBI
30	Nordestgaard BG and Zacho J: Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 19:521–524. 2009. View Article : Google Scholar : PubMed/NCBI
31	Adachi K, Miyajima SI, Nakamura N, Miyabe M, Kobayashi Y, Nishikawa T, Suzuki Y, Kikuchi T, Kobayashi S, Saiki T, et al: Role of Poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes. J Clin Periodontol. 44:971–980. 2017. View Article : Google Scholar : PubMed/NCBI
32	Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, Boulares AH and Pacher P: Poly(ADP-ribose)polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med. 51:1774–1788. 2011. View Article : Google Scholar : PubMed/NCBI
33	Cardinale A, Paldino E, Giampà C, Bernardi G and Fusco FR: PARP-1 inhibition is neuroprotective in the R6/2 mouse model of Huntington's disease. PLoS One. 10:e1344822015. View Article : Google Scholar
34	Sun M, Zhao Y, Gu Y and Xu C: Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB. Amino Acids. 42:1735–1747. 2012. View Article : Google Scholar : PubMed/NCBI
35	Besson VC, Zsengellér Z, Plotkine M, Szabó C and Marchand-Verrecchia C: Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat. Brain Res. 1041:149–156. 2005. View Article : Google Scholar : PubMed/NCBI
36	Komirishetty P, Areti A, Gogoi R, Sistla R and Kumar A: Combination strategy of PARP inhibitor with antioxidant prevent bioenergetic deficits and inflammatory changes in CCI-induced neuropathy. Neuropharmacology. 113:137–147. 2017. View Article : Google Scholar : PubMed/NCBI
37	Song ZF, Ji XP, Li XX, Wang SJ, Wang SH and Zhang Y: Inhibition of the activity of poly (ADP-ribose) polymerase reduces heart ischaemia/reperfusion injury via suppressing JNK-mediated AIF translocation. J Cell Mol Med. 12:1220–1228. 2008. View Article : Google Scholar : PubMed/NCBI
38	Pandya KG, Patel MR and Lau-Cam CA: Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide. J Biomed Sci. 17 Suppl 1:S162010. View Article : Google Scholar : PubMed/NCBI
39	Finn RS, Lau A, Kalous O, Conklin D, Dering J, Knights C, O Shaughnessy A, Cranston A, Riches L and Carmichael J: Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents. Cancer Res. 69:10382009. View Article : Google Scholar
40	Sandhu SK, Yap TA and de Bono JS: Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. Eur J Cancer. 46:9–20. 2010. View Article : Google Scholar : PubMed/NCBI
41	d'Avila JC, Lam TI, Deborah B, Shi J, Won SJ, Kauppinen TM, Massa S, Liu J and Swanson RA: Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J Neuroinflamm. 9:312012.
42	Nakajima H, Nagaso HN, Ishikawa M, Hiranuma T and Hoshiko S: Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-kappaB-dependent gene expression in primary cultured mouse glial cells. J Biol Chem. 279:42774–42786. 2004. View Article : Google Scholar : PubMed/NCBI
43	Chen F, Castranova V, Shi X and Demers LM: New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem. 45:7–17. 1999.PubMed/NCBI
44	You WC, Wang CX, Pan YX, Zhang X, Zhou XM, Zhang XS, Shi JX and Zhou ML: Activation of nuclear factor-κB in the brain after experimental subarachnoid hemorrhage and its potential role in delayed brain injury. PLoS One. 8:e602902013. View Article : Google Scholar : PubMed/NCBI
45	Hassa PO and Hottiger MO: The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci. 59:1534–1553. 2002. View Article : Google Scholar : PubMed/NCBI
46	Castri P, Lee YJ, Ponzio T, Maric D, Spatz M, Bembry J and Hallenbeck J: Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-kappaB-dependent signaling. Biochim Biophys Acta. 1843:640–651. 2014. View Article : Google Scholar : PubMed/NCBI
47	Chen T, Wang W, Li JR, Xu HZ, Peng YC, Fan LF, Yan F, Gu C, Wang L and Chen G: PARP inhibition attenuates early brain injury through NF-κB/MMP-9 pathway in a rat model of subarachnoid hemorrhage. Brain Res. 1644:32–38. 2016. View Article : Google Scholar : PubMed/NCBI